A phase I, dose-escalation, sequential-cohort study of the safety, tolerability, and pharmacokinetics of intravenous AVE0005 (VEGF Trap) [aflibercept] in combination with intravenous docetaxel/cisplatin/5-fluorouracil administered every 3 weeks in subjects with advanced solid malignancies

Trial Profile

A phase I, dose-escalation, sequential-cohort study of the safety, tolerability, and pharmacokinetics of intravenous AVE0005 (VEGF Trap) [aflibercept] in combination with intravenous docetaxel/cisplatin/5-fluorouracil administered every 3 weeks in subjects with advanced solid malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Aflibercept; Cisplatin; Docetaxel; Fluorouracil
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 31 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top